Lukang Pharmaceutical gets CSRC approval for targeted share issuance

Shandong Lukang Pharmaceutical Co., Ltd. ("the Company") recently announced it has obtained approval from the China Securities Regulatory Commission (CSRC) for the registration of its application to issue shares to specific targets. The approval allows the Company to proceed with the issuance as per the submitted documents and plan to the Shanghai Stock Exchange.

The approval is valid for 12 months from the date of registration. The Company's board of directors will manage the share issuance within this timeframe, adhering to the approval documents, relevant laws, regulations, and resolutions from the general meeting of shareholders. Investors are advised to be aware of investment risks.